Status:
UNKNOWN
Quality of Life in Patients Who Have Undergone Previous Treatment for Primitive Neuroectodermal Tumors
Lead Sponsor:
Children's Cancer and Leukaemia Group
Conditions:
Brain and Central Nervous System Tumors
Cognitive/Functional Effects
Eligibility:
All Genders
3-24 years
Brief Summary
RATIONALE: Questionnaires that measure quality of life may improve the ability to plan treatment for patients with primitive neuroectodermal tumors. PURPOSE: This phase III trial is studying quality ...
Detailed Description
OBJECTIVES: Primary * Determine the quality of survival of patients in the UK and other European countries enrolled in previous International Society of Pediatric Oncology (SIOP) 2 or 3 phase III tr...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Surviving primitive neuroectodermal tumor (PNET) patients previously enrolled in International Pediatric Oncology Society (SIOP) 2 or 3 phase III treatment trials
- Surviving PNET patients eligible for and treated according to PNET 3 protocol but not randomized
- No metastatic disease at time of allocation to treatment
- No current progressive disease
- PATIENT CHARACTERISTICS:
- No patient deemed unsuitable for this study by treating clinician
- PRIOR CONCURRENT THERAPY:
- Not specified
Exclusion
Key Trial Info
Start Date :
June 1 2002
Trial Type :
OBSERVATIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00278239
Start Date
June 1 2002
Last Update
September 20 2013
Active Locations (21)
Enter a location and click search to find clinical trials sorted by distance.
1
Our Lady's Hospital for Sick Children
Dublin, Ireland, 12
2
Birmingham Children's Hospital
Birmingham, England, United Kingdom, B4 6NH
3
Institute of Child Health at University of Bristol
Bristol, England, United Kingdom, BS2 8AE
4
Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust
Cambridge, England, United Kingdom, CB2 2QQ